Article info

Download PDFPDF
Dose escalation of infliximab in clinical practice: improvements seen may be explained by a regression-like effect
  1. Correspondence to:
    Dr Ronald F van Vollenhoven
    Department of Rheumatology, Karolinska Hospital, D2-1, 17176 Stockholm, Sweden; ronald.vanvollenhovenks.se
View Full Text

Citation

van Vollenhoven RF, Brannemark S, Klareskog L
Dose escalation of infliximab in clinical practice: improvements seen may be explained by a regression-like effect

Publication history

  • Accepted June 29, 2003
  • First published February 27, 2004.
Online issue publication 
October 25, 2017

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.